Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment
2011

HIV Treatment in Children with Tuberculosis

Sample size: 526 publication 10 minutes Evidence: moderate

Author Information

Author(s): Frohoff Cordula, Moodley Magendhree, Fairlie Lee, Coovadia Ashraf, Moultrie Harry, Kuhn Louise, Meyers Tammy

Primary Institution: Columbia University

Hypothesis

Modification of antiretroviral therapy is required for HIV-infected children co-treated for tuberculosis.

Conclusion

Good short-term virologic outcomes were achieved in children co-treated for TB and HIV who received super-boosted LPV/r, with rare treatment-limiting toxicity.

Supporting Evidence

  • Children receiving super-boosted LPV/r had similar viral suppression rates to comparisons at 6 months.
  • Children in the ritonavir group had significantly lower rates of viral suppression compared to comparisons.
  • Treatment interruptions due to toxicity were rare among the co-treated children.

Takeaway

This study looked at how different HIV treatments work for kids who also have tuberculosis, finding that a special boosted treatment works well without causing too many side effects.

Methodology

A retrospective medical record review was conducted at two clinical sites in Johannesburg, South Africa, comparing children co-treated for TB with those not treated for TB.

Potential Biases

Potential biases may arise from the retrospective nature of the study and the selection of participants.

Limitations

The study is retrospective and may have limitations related to data accuracy and completeness.

Participant Demographics

Children aged 6–24 months, with 294 (56%) co-treated for TB.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0017273

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication